Nature Biotechnology
(2026) Cite this article
Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Dispatch Bio delivers antigens to solid tumors for CAR T immunotherapy.
Cucolo, L. et al. J. Immunother. Cancer https://doi.org/10.1136/jitc-2025-SITC2025.0393 (2025).
Liu, R. et al. J. Immunother. Cancer https://doi.org/10.1136/jitc-2025-SITC2025.0394 (2025).
Johnson, J. L. et al. Mol. Ther. 35, S3278 (2026).
Roybal, K. T. et al. Cell 167, 419–432.e16 https://doi.org/10.1016/j.cell.2016.09.011 (2016).
Jiang, H. et al. Immunity 59, 177–194e12 https://doi.org/10.1016/j.immuni.2025.10.024 (2026).
Geyer, M. B. et al. Blood 146, 3163–3174 https://doi.org/10.1182/blood.2025029532 (2025).
Garber, K. Editor’s pick: Dispatch Biotherapeutics.
Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03293-z
DOI: https://doi.org/10.1038/s41587-026-03293-z
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
